Cargando…

Treatment of central serous chorioretinopathy with topical NSAIDs

PURPOSE: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery. METHODS: An IRB-approved retrospective review wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahadorani, Sepehr, Maclean, Kyle, Wannamaker, Kendall, Chu, Edward Rickie, Gresores, Nathan, Sohn, Jeong-Hyeon, Diaz-Rohena, Roberto, Singer, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699520/
https://www.ncbi.nlm.nih.gov/pubmed/31616132
http://dx.doi.org/10.2147/OPTH.S202047
_version_ 1783444742798835712
author Bahadorani, Sepehr
Maclean, Kyle
Wannamaker, Kendall
Chu, Edward Rickie
Gresores, Nathan
Sohn, Jeong-Hyeon
Diaz-Rohena, Roberto
Singer, Michael A
author_facet Bahadorani, Sepehr
Maclean, Kyle
Wannamaker, Kendall
Chu, Edward Rickie
Gresores, Nathan
Sohn, Jeong-Hyeon
Diaz-Rohena, Roberto
Singer, Michael A
author_sort Bahadorani, Sepehr
collection PubMed
description PURPOSE: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery. METHODS: An IRB-approved retrospective review was conducted on patients that had been diagnosed with a new-onset, symptomatic case of CSCR. Patients were either observed only (13 untreated eyes) or treated with topical bromfenac or nepafenac (14 eyes) over an average of about a 4–5 week follow-up period. RESULTS: There was no statistical significance between central macular thickness (CMT) and visual acuity of treatment and control groups at the initial presentation. However, at the follow-up visit, CMT reductions in the treatment group were significantly higher than in the control group (p<0.006). CONCLUSION: Use of topical NSAIDs in the treatment of acute CSCR leads to a faster rate of reduction in the subretinal fluid volume over a follow-up period of a few weeks.
format Online
Article
Text
id pubmed-6699520
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66995202019-10-15 Treatment of central serous chorioretinopathy with topical NSAIDs Bahadorani, Sepehr Maclean, Kyle Wannamaker, Kendall Chu, Edward Rickie Gresores, Nathan Sohn, Jeong-Hyeon Diaz-Rohena, Roberto Singer, Michael A Clin Ophthalmol Original Research PURPOSE: Central serous chorioretinopathy (CSCR) is a common retinopathy that is often observed until resolution. The purpose of this study is to evaluate the effects of topical nonsteroidal anti-inflammatory drugs (NSAIDs) on timing of CSCR recovery. METHODS: An IRB-approved retrospective review was conducted on patients that had been diagnosed with a new-onset, symptomatic case of CSCR. Patients were either observed only (13 untreated eyes) or treated with topical bromfenac or nepafenac (14 eyes) over an average of about a 4–5 week follow-up period. RESULTS: There was no statistical significance between central macular thickness (CMT) and visual acuity of treatment and control groups at the initial presentation. However, at the follow-up visit, CMT reductions in the treatment group were significantly higher than in the control group (p<0.006). CONCLUSION: Use of topical NSAIDs in the treatment of acute CSCR leads to a faster rate of reduction in the subretinal fluid volume over a follow-up period of a few weeks. Dove 2019-08-15 /pmc/articles/PMC6699520/ /pubmed/31616132 http://dx.doi.org/10.2147/OPTH.S202047 Text en © 2019 Bahadorani et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bahadorani, Sepehr
Maclean, Kyle
Wannamaker, Kendall
Chu, Edward Rickie
Gresores, Nathan
Sohn, Jeong-Hyeon
Diaz-Rohena, Roberto
Singer, Michael A
Treatment of central serous chorioretinopathy with topical NSAIDs
title Treatment of central serous chorioretinopathy with topical NSAIDs
title_full Treatment of central serous chorioretinopathy with topical NSAIDs
title_fullStr Treatment of central serous chorioretinopathy with topical NSAIDs
title_full_unstemmed Treatment of central serous chorioretinopathy with topical NSAIDs
title_short Treatment of central serous chorioretinopathy with topical NSAIDs
title_sort treatment of central serous chorioretinopathy with topical nsaids
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699520/
https://www.ncbi.nlm.nih.gov/pubmed/31616132
http://dx.doi.org/10.2147/OPTH.S202047
work_keys_str_mv AT bahadoranisepehr treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT macleankyle treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT wannamakerkendall treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT chuedwardrickie treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT gresoresnathan treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT sohnjeonghyeon treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT diazrohenaroberto treatmentofcentralserouschorioretinopathywithtopicalnsaids
AT singermichaela treatmentofcentralserouschorioretinopathywithtopicalnsaids